3.49
3.49 (0%)
As of Dec 18, 2023
Neoleukin Therapeutics, Inc. [NLTX]
Source:
Company Overview
Neurogene Inc. is a clinical-stage biotechnology company committed to overcoming these limitations and turning today’s complex devastating neurological diseases into treatable conditions. By harnessing our proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning), we are building a robust and differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet need not otherwise addressable by conventional gene therapy.
| Country | United States |
| Headquarters | new york, new york |
| Phone Number | ( 855 ) 508-3568 |
| Industry | manufacturing |
| CEO | Rachel Mcminn |
| Website | www.neurogene.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.9 |
| Operating Profit | $-82.6 |
| Net Income | $-75.1 |
| Net Cash | $-11.8 |
Profit Ratios
| Gross Margin | $0.9 |
| Operating Margin | -8,930.3 |
| Profit as % of Revenues | -1.2% |
| Profit as % of Assets | -26.9% |
| Profit as % of Stockholder Equity | -24.2% |
Management Effectiveness
| Return on Equity | -24.2% |
| Return on Assets | -22.4% |
| Turnover Ratio | 0.3% |
| EBITA | $-82.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $335.7 |
| Total Liabilities | $25.4 |
| Operating Cash Flow | $-70.6 |
| Investing Cash Flow | $-125.3 |
| Financing Cash Flow | $184.1 |
